What does the HAS-BLED score mean?

HAS-BLED estimates the 1-year risk of major bleeding in patients with atrial fibrillation. Each letter represents a risk factor: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly (>65), Drugs/Alcohol. Scores range from 0 to 9.

What is a high HAS-BLED score?

A score ≥ 3 indicates high risk of major bleeding. However, a high score does not mean anticoagulation should be stopped — it means modifiable risk factors should be addressed and the patient should be monitored more closely.

Should I stop anticoagulation if HAS-BLED is high?

No. A high HAS-BLED score is not a contraindication to anticoagulation. Studies show that patients with high [CHA₂DS₂-VASc](/tools/cha2ds2-vasc) AND high HAS-BLED scores still benefit from anticoagulation. Focus on correcting modifiable risk factors (blood pressure control, limiting alcohol, stopping unnecessary NSAIDs).

How often should bleeding risk be reassessed?

Bleeding risk should be reassessed periodically, typically at each clinic visit or at least annually. Risk factors can change over time, and ongoing reassessment helps optimize the balance between stroke prevention and bleeding risk.

What is the major bleeding rate by HAS-BLED score?

Score 0: 1.13%/year. Score 1: 1.02%/year. Score 2: 1.88%/year. Score 3: 3.74%/year. Score 4: 8.70%/year. Score ≥5: 12.50%/year. These rates are from the original Euro Heart Survey validation.

What counts as major bleeding?

Major bleeding typically means bleeding requiring hospitalization, causing hemoglobin drop ≥2 g/dL, requiring transfusion, or occurring in a critical site (intracranial, intraocular, retroperitoneal, pericardial, or muscle compartment).

Is HAS-BLED validated for DOACs?

HAS-BLED was developed in warfarin-treated patients. While commonly used for DOAC patients, the labile INR criterion doesn't apply. Some DOAC-specific scores exist but HAS-BLED remains widely used due to familiarity and simplicity.

What is the difference between HAS-BLED and ATRIA?

ATRIA is an alternative bleeding risk score using different criteria (anemia, severe renal disease, age ≥75, prior bleeding, hypertension). Both predict major bleeding in AFib. HAS-BLED is more widely used in Europe and endorsed by ESC guidelines.

How does hypertension score — any hypertension or uncontrolled?

Score a point for uncontrolled hypertension, specifically systolic BP >160 mmHg. Well-controlled hypertension on medication typically does not score a point, though definitions vary in practice.

What does 'drugs' include?

Concomitant use of antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor) or NSAIDs (ibuprofen, naproxen, etc.) scores 1 point. Each category doesn't add separately — it's 1 point total for any of these drug classes.

Should I use HAS-BLED or HEMORR2HAGES?

HAS-BLED is simpler (9 criteria vs. 11) and more commonly used. HEMORR2HAGES includes genetic factors and was developed earlier. ESC guidelines recommend HAS-BLED. Use what your institution prefers.

Can HAS-BLED predict intracranial hemorrhage specifically?

HAS-BLED predicts major bleeding overall, not specifically ICH. ICH is the most feared complication but represents a minority of major bleeds. Risk factors for ICH (prior ICH, severe hypertension, antiplatelet use) overlap with HAS-BLED criteria.

What TTR threshold defines labile INR?

Time in therapeutic range (TTR) <60% is commonly used to define poor INR control / labile INR. If you don't know TTR, use clinical judgment: frequent dose adjustments, wide INR swings, or difficulty achieving stable anticoagulation.

Does chronic kidney disease automatically score a point?

Only if severe: chronic dialysis, renal transplantation, or creatinine ≥2.3 mg/dL (200 µmol/L). Moderate CKD (eGFR 30-60) alone doesn't score a point by the original criteria, though it does increase bleeding risk.

How do I interpret HAS-BLED alongside CHA2DS2-VASc?

Calculate both. If CHA2DS2-VASc indicates anticoagulation benefit (≥1 men, ≥2 women), anticoagulate. If HAS-BLED is high (≥3), address modifiable factors and monitor closely. Only in rare cases does high bleeding risk outweigh stroke benefit.

Online Medical Tools — HAS-BLED Score

Printed on 8/14/2026

For informational purposes only. This is not medical advice.

Cardiology

HAS-BLED Score

The HAS-BLED score estimates the risk of major bleeding in patients with atrial fibrillation who are on or being considered for anticoagulation therapy. It is meant to be used alongside the CHA₂DS₂-VASc score to weigh stroke prevention benefits against bleeding risk. A high HAS-BLED score does not contraindicate anticoagulation but highlights the need for careful monitoring.

Formula: Score = H(1) + A(1+1) + S(1) + B(1) + L(1) + E(1) + D(1+1)

Hypertension (SBP > 160)

Renal Disease

Liver Disease

Stroke History

Prior Major Bleeding

Labile INR

Age > 65

Drugs (Antiplatelets/NSAIDs)

Alcohol Use (≥ 8 drinks/week)

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Answer each bleeding risk factor

Select yes or no for each of the nine risk factors. Each 'yes' adds 1 point, with renal/liver and drugs/alcohol potentially adding 2 points each.

Calculate your total score

The calculator sums your points, producing a score from 0 to 9. Higher scores indicate greater annual major bleeding risk.

Identify modifiable risk factors

Review which risk factors can be corrected — blood pressure, labile INR, NSAIDs, alcohol. Addressing these reduces bleeding risk while maintaining anticoagulation benefit.

Who Uses the HAS-BLED Score

Anticoagulation Initiation

Cardiologists, internists

Calculate HAS-BLED alongside [CHA2DS2-VASc](/tools/cha2ds2-vasc) when deciding whether to start anticoagulation. Even high bleeding risk usually doesn't preclude anticoagulation.

Patient Counseling

Physicians, pharmacists

Use the score to have informed conversations about bleeding risk, explaining which factors are modifiable and what monitoring will look like.

Annual Reassessment

Primary care, cardiology clinics

Recalculate yearly as risk factors change. New hypertension, renal disease, or medication changes can increase the score and warrant closer monitoring.

INR Management

Anticoagulation clinics

Patients with labile INR (score point) need closer INR monitoring or consideration of DOAC switch. The score flags who needs more intensive management.

Pre-Procedure Planning

Surgeons, proceduralists

Quantify bleeding risk before procedures requiring anticoagulation interruption. High HAS-BLED may influence bridging decisions and timing.

Net Clinical Benefit Assessment

Guideline committees, researchers

Compare [CHA2DS2-VASc](/tools/cha2ds2-vasc) against HAS-BLED to assess whether anticoagulation provides net benefit. Most patients benefit even when both scores are elevated.

Pro Tips

High HAS-BLED does NOT mean stop anticoagulation

This is the most important point. Studies consistently show patients with high [CHA2DS2-VASc](/tools/cha2ds2-vasc) and high HAS-BLED still derive net benefit from anticoagulation. The score guides monitoring and risk factor modification, not whether to anticoagulate.

Focus on modifiable risk factors

Hypertension (control BP), labile INR (improve TTR or switch to DOAC), drugs (stop unnecessary NSAIDs/antiplatelets), and alcohol (reduce consumption) are all addressable. Fixing these reduces bleeding risk without stopping anticoagulation.

Labile INR doesn't apply to DOACs

The labile INR criterion was developed for warfarin. For patients on DOACs, this point doesn't apply since there's no INR to monitor. Some experts suggest scoring 0 for this criterion in DOAC patients.

Renal disease definition

Score a point for chronic dialysis, renal transplantation, or serum creatinine ≥2.3 mg/dL (200 µmol/L). Moderate CKD alone may not meet the threshold — check the original criteria.

Liver disease definition

Score a point for chronic hepatic disease (cirrhosis) OR biochemical evidence of significant hepatic derangement (bilirubin >2× ULN with AST/ALT/ALP >3× ULN). Mild liver enzyme elevations don't count.

Prior bleeding includes any major hemorrhage

Major bleeding means requiring hospitalization, hemoglobin drop ≥2 g/dL, and/or transfusion. GI bleeds, intracranial hemorrhage, and major trauma bleeds all count. Minor bruising does not.

Age is non-modifiable but actionable

You can't change a patient's age, but you can ensure elderly patients (>65) have fall prevention in place, avoid concurrent NSAIDs, and have closer INR monitoring if on warfarin.

Compare before and after interventions

If a patient starts with HAS-BLED 4 and you control their BP, stop their NSAID, and improve TTR, they might drop to HAS-BLED 2. Show patients the score can improve with effort.

Don't use aspirin as a 'safer' alternative

Aspirin doesn't prevent stroke effectively in AFib and still carries bleeding risk. Current guidelines recommend against aspirin monotherapy for AFib stroke prevention. It's anticoagulation or nothing.

Document the score in your note

Recording HAS-BLED alongside [CHA2DS2-VASc](/tools/cha2ds2-vasc) demonstrates you've considered bleeding risk. It protects you medicolegally and ensures the next provider sees your risk assessment.

Common Questions About Your Results

Evidence-Based Methodology

HAS-BLED was developed by Pisters et al. (Chest 2010) from the Euro Heart Survey on Atrial Fibrillation. It is endorsed by ESC (2020) and NICE guidelines. Studies confirm net clinical benefit of anticoagulation even in high HAS-BLED patients when CHA2DS2-VASc indicates stroke risk (Olesen et al., JACC 2011).

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Your HAS-BLED score ranges from 0 to 9 and estimates the 1-year risk of major bleeding in patients with atrial fibrillation on anticoagulation. A score of 0 corresponds to a major bleeding risk of approximately 1.13% per year. A score of 1 carries roughly 1.02% risk, and a score of 2 carries approximately 1.88% risk. A score of 3 or higher is classified as high risk, with bleeding rates of 3.74% and above, increasing with each additional point.

Critically, a high HAS-BLED score does not mean anticoagulation should be withheld. Studies consistently show that patients with both high CHA₂DS₂-VASc and high HAS-BLED scores derive net clinical benefit from anticoagulation. The score's primary purpose is to identify patients who need closer monitoring and correction of modifiable bleeding risk factors.

When to Use This Tool

Use this calculator alongside the CHA₂DS₂-VASc score whenever evaluating anticoagulation therapy in a patient with atrial fibrillation. It should be assessed at the time of initiating anticoagulation, during follow-up visits, and whenever a patient's clinical status changes — for example, new onset of uncontrolled hypertension, initiation of antiplatelet therapy or NSAIDs, or a change in alcohol consumption.

The score is also useful for structuring conversations with patients about the risks and benefits of anticoagulation. Identifying modifiable risk factors (uncontrolled blood pressure, labile INR, concurrent antiplatelet or NSAID use, excessive alcohol) provides actionable targets to reduce bleeding risk while maintaining anticoagulation.

Limitations

The HAS-BLED score was developed and validated primarily in patients taking vitamin K antagonists (warfarin), where labile INR is a relevant risk factor. For patients on direct oral anticoagulants (DOACs), the labile INR criterion does not apply, and the score may be less calibrated. Some experts suggest assigning 0 for labile INR in DOAC users, but this has not been formally validated.

The score treats all risk factors equally (1 point each), which may not reflect the true relative contribution of each factor to bleeding risk. A patient with active liver disease and a history of major hemorrhage is likely at substantially higher risk than a patient whose only points come from age over 65 and moderate alcohol use. Additionally, the score does not capture certain bleeding risk factors such as thrombocytopenia, concurrent use of other anticoagulants, or recent falls history in elderly patients. Clinical judgment remains essential.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools